These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 8544678)

  • 1. The relevance of searching for effects under a clinical-trial lamppost: a key issue.
    Rittenhouse BE
    Med Decis Making; 1995; 15(4):348-57. PubMed ID: 8544678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies.
    Evers SM; Hiligsmann M; Adarkwah CC
    Psychol Health; 2015 Jan; 30(1):52-71. PubMed ID: 25141273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.
    Ishak KJ; Caro JJ; Drayson MT; Dimopoulos M; Weber D; Augustson B; Child JA; Knight R; Iqbal G; Dunn J; Shearer A; Morgan G
    Value Health; 2011; 14(5):672-8. PubMed ID: 21839405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytic considerations in economic evaluations of multinational cardiovascular clinical trials.
    Torti FM; Reed SD; Schulman KA
    Value Health; 2006; 9(5):281-91. PubMed ID: 16961546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biologicals first-line in chronic inflammatory bowel disease? No].
    Herrlinger K; Stange EF
    Dtsch Med Wochenschr; 2011 Sep; 136(36):1789. PubMed ID: 21882135
    [No Abstract]   [Full Text] [Related]  

  • 7. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.
    Ray JA; Carr E; Lewis G; Marcus R
    Value Health; 2010; 13(4):346-57. PubMed ID: 20070643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality?
    Weisberg HI; Hayden VC; Pontes VP
    Clin Trials; 2009 Apr; 6(2):109-18. PubMed ID: 19342462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system.
    Neubauer AS; Holz FG; Sauer S; Wasmuth T; Hirneiss C; Kampik A; Schrader W
    Clin Ther; 2010 Jul; 32(7):1343-56. PubMed ID: 20678682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
    Pascual J
    Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
    Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    Trials; 2014 Dec; 15():502. PubMed ID: 25528663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some main problems eroding the credibility and relevance of randomized trials.
    Ioannidis JP
    Bull NYU Hosp Jt Dis; 2008; 66(2):135-9. PubMed ID: 18537784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generalizing results of randomized trials to clinical practice: reliability and cautions.
    Flather M; Delahunty N; Collinson J
    Clin Trials; 2006; 3(6):508-12. PubMed ID: 17170034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches to economic evaluation in telemedicine.
    Bergmo TS
    J Telemed Telecare; 2012 Jun; 18(4):181-4. PubMed ID: 22619374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
    Jönsson L; Borgström F; Zethraeus N
    Ugeskr Laeger; 2003 Oct; 165(43):4112-6. PubMed ID: 14619061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.